Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
iShares Genomics Immunology and Healthcare ETF (IDNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: IDNA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit -12.88% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | ETF Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Volume (30-day avg) - | Beta 1.08 | 52 Weeks Range 17.14 - 25.49 | Updated Date 06/30/2025 |
52 Weeks Range 17.14 - 25.49 | Updated Date 06/30/2025 |
Upturn AI SWOT
iShares Genomics Immunology and Healthcare ETF
ETF Overview
Overview
The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the investment results of an index composed of companies that could benefit from the long-term growth and innovation in the genomics, immunology and bioengineering industries. It offers exposure to global companies involved in these transformative healthcare fields.
Reputation and Reliability
BlackRock is one of the world's largest asset managers with a strong reputation and proven track record in the ETF market.
Management Expertise
BlackRock has a dedicated team of portfolio managers and analysts with deep expertise in thematic investing and healthcare.
Investment Objective
Goal
To track the investment results of an index composed of companies that could benefit from the long-term growth and innovation in the genomics, immunology and bioengineering industries.
Investment Approach and Strategy
Strategy: The ETF seeks to track the ICE Genomic Immunology and Healthcare Index, a rules-based index designed to represent companies involved in genomics, immunology and healthcare.
Composition The ETF holds a basket of global stocks involved in genomics, immunology, and healthcare, offering diversified exposure to these sectors.
Market Position
Market Share: Details regarding IDNA's exact market share are difficult to determine precisely due to the niche and evolving nature of the genomics/immunology ETF market. Determining IDNA's market share would require analyzing data from all ETFs operating in related sectors.
Total Net Assets (AUM): 212463407
Competitors
Key Competitors
- ARKG
- GNOM
- CRSP
- XBI
Competitive Landscape
The competitive landscape includes broader biotech ETFs and more narrowly focused genomics ETFs. IDNA provides a diversified exposure to the confluence of genomics, immunology, and healthcare, whereas ARKG's market share is larger due to its active management style. Conversely, XBI tracks an equal-weighted biotechnology index, while GNOM and CRSP have a smaller market share.
Financial Performance
Historical Performance: Historical performance data needs to be obtained from financial data providers like Bloomberg, Yahoo Finance, or iShares official site to fill in with numerical data to show the ETFs performance over the different time periods.
Benchmark Comparison: Benchmark comparison requires the historical performance data from the financial data providers like Bloomberg, Yahoo Finance, or iShares official site to directly compare to the ETF.
Expense Ratio: 0.47
Liquidity
Average Trading Volume
The average trading volume for IDNA indicates adequate liquidity for most investors.
Bid-Ask Spread
The bid-ask spread for IDNA can vary depending on market conditions, however, it is generally tight.
Market Dynamics
Market Environment Factors
The ETF is influenced by factors such as advancements in genomics and immunology, regulatory approvals for new therapies, and overall healthcare spending trends.
Growth Trajectory
The ETF's growth trajectory is tied to the increasing adoption of genomic technologies, advancements in immunotherapy, and the growing demand for innovative healthcare solutions.
Moat and Competitive Advantages
Competitive Edge
IDNA's competitive advantage lies in its focus on the intersection of genomics, immunology, and healthcare which gives targeted exposure to key healthcare themes. BlackRock's reputation and expertise contribute to investor confidence. The ETF is focused and provides access to companies involved in the innovation and growth of genomics, immunology and bioengineering industries. Also the ETF is rules-based and tracks an index of companies involved in this rapidly growing industry, giving broader exposure.
Risk Analysis
Volatility
IDNA's volatility is expected to be moderate to high, reflecting the growth-oriented nature of the underlying sectors.
Market Risk
The ETF is subject to market risk, sector-specific risk (healthcare, biotech), and the risk associated with investing in companies involved in innovative technologies.
Investor Profile
Ideal Investor Profile
IDNA is suitable for investors seeking long-term growth potential through exposure to innovative healthcare technologies, particularly those interested in genomics and immunology.
Market Risk
IDNA is best suited for long-term investors with a higher risk tolerance.
Summary
The iShares Genomics Immunology and Healthcare ETF (IDNA) offers exposure to global companies that could benefit from the long-term growth and innovation in the genomics, immunology and bioengineering industries. The ETF focuses on genomic sequencing, gene editing, and personalized medicine, the ETF is suitable for investors seeking growth potential in innovative healthcare technologies. BlackRock's reputation and the ETF's targeted approach could attract investor interest. The ETF's performance depends on the advancements in genomics, immunology, and healthcare, which will appeal to investors who want to participate in this emerging sector.
Peer Comparison
Sources and Disclaimers
Data Sources:
- iShares Website
- Bloomberg
- Yahoo Finance
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be made based on individual circumstances and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iShares Genomics Immunology and Healthcare ETF
Exchange NYSE ARCA | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. -null-.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.